Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2021-03-25 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2020年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2020 年年度报告摘要" which translates to "2020 Annual Report Summary". It contains detailed financial data for the year 2020, including revenue, net profit, quarterly breakdowns, and business operations discussion. It also includes information about company business, product development, and management discussion. The document is over 12,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of audited financial data and comprehensive business analysis aligns with the characteristics of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification, nor is it a quarterly or interim report. Therefore, the document is best classified as an Annual Report (10-K). FY 2020
2021-03-25 Chinese
平安证券股份有限公司关于公司2020年度募集资金存放与使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Ping An Securities regarding the 2020 annual verification of the use and storage of raised funds by Yunnan Watson Biotechnology Co., Ltd. It includes extensive financial data on fundraising amounts, usage, bank accounts, investment projects, changes in project implementation, and compliance with relevant laws and regulations. The document is lengthy (15,000 characters) and contains substantive financial data and analysis related to the company's fundraising activities and capital usage for the fiscal year 2020. It is not merely an announcement or a certification but a comprehensive report on fundraising capital usage and compliance. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2021-03-25 Chinese
关于沃森生物科技创新中心项目调整的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about adjustments to a specific capital investment project (the Watson Biological Technology Innovation Center project). It discusses changes in project scale, investment amount, construction timeline, and funding sources. It includes approvals from the board, supervisory board, independent directors, and financial advisors. The document focuses on the use and adjustment of raised funds and project progress, which is typical of a capital/financing update. There is no indication that this is a full annual or interim report, audit report, earnings release, or other types of filings. The document is longer than 5,000 characters and contains substantive content about capital project adjustments, not just an announcement of a report publication. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-03-25 Chinese
关于调整部分募集资金投资项目达到预定可使用状态时间的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the adjustment of the expected usable date of certain investment projects funded by raised capital. It details the status of the fundraising, the progress of the investment projects, reasons for the adjustment, and includes opinions from the board, independent directors, and the sponsoring securities firm. The document does not contain financial statements or detailed financial performance data but focuses on the use and timing of capital raised through fundraising activities. This fits the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage. The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it provides substantive information about the capital usage adjustment. Therefore, the correct classification is CAP with high confidence.
2021-03-25 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about a change in accounting policy, specifically regarding the adoption of a new lease accounting standard effective from January 1, 2021. It details the reasons for the change, the new policy, its impact, and approvals from the board and independent directors. The document does not contain full financial statements or comprehensive financial performance data, nor is it a full annual or interim report. It is a regulatory announcement about an accounting policy change, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure rather than a full report or financial statement.
2021-03-25 Chinese
2020年度募集资金存放与实际使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2020年度募集资金存放与实际使用情况专项报告" which translates to "2020 Annual Report on the Deposit and Actual Use of Raised Funds." It details the amounts of funds raised through stock issuance, their deposit in special accounts, usage over multiple years, and management of these funds. It includes detailed financial figures related to fundraising, usage, and balances, as well as descriptions of regulatory approvals and agreements with banks for fund management. The document is comprehensive and contains substantive financial data about fundraising and capital usage, not merely an announcement or certification. This aligns with the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an Annual Report (10-K) or Interim Report (IR) as it focuses specifically on fundraising and use of proceeds rather than full financial performance. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains detailed data and is not just a notice or certification. Therefore, the best classification is CAP with high confidence.
2021-03-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.